Due to its highly potent and membrane-permeable cytotoxic payload, along with its enzyme-cleavable antibody–drug linker and high drug-to-antibody ratio, trastuzumab deruxtecan has antitumor activity in breast cancers with low levels of HER2 through the bystander effect20. The gene discussed is ERBB2; the disease is breast carcinoma.